Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono Sets Course for Growth Beyond Opdivo Patent Cliff
Ono Pharmaceutical is charting a path to sustainable growth despite the looming global patent expiry of its flagship PD-1 antibody Opdivo (nivolumab), President and COO Toichi Takino said on March 24. “We now have an outlook for offsetting Opdivo’s LOE…
To read the full story
BUSINESS
- Ono Sets Course for Growth Beyond Opdivo Patent Cliff
March 25, 2026
- Fuji, Richter Strike Co-Development Pact in Women’s Health
March 25, 2026
- ASKA Inks AI Target Discovery Pact with Insilico in Women’s Health
March 25, 2026
- Shionogi to Fully Acquire Sleep Disorder JV SASS
March 25, 2026
- Stella Pharma Files Steboronine for Angiosarcoma
March 25, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…